Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab, Trastuzumab, and Paclitaxel in Metastatic HER2-Positive Breast Cancer
NCT01276041Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2011
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab in HER2-positive metastatic breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2011; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01276041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01276041.